Pillstats
Rx only · Injection, Solution · Subcutaneous

Insulin Lispro-Aabc

Brands: Lyumjev · Lyumjev Junior Kwikpen · Lyumjev Kwikpen · Lyumjev Tempo Pen · Insulin Lispro

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US5 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)86009
US makers1 labelers
Packages7
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$12.98$25.96$38.94$51.92Nov 2025Feb 2026Jul 2026
$13.532
Latest avg · Jul 22, 2026
-60%
Since Nov 19, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1.0K2.0K3.0K4.0K2025 Q12025 Q22025 Q32025 Q42026 Q1
3.4K
Rx · 2026 Q1
78K
Units dispensed
+6%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Eli Lilly and Companyunknown7SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Oct 24, 2025
    RESOLVEDShortage resolved: Insulin Lispro-aabc Injection (Eli Lilly and Co.)

    Insulin Lispro-aabc Injection — reported in shortage by Eli Lilly and Co.. Therapeutic category: Endocrinology/Metabolism.

  • Oct 24, 2025
    SHORTAGEDrug shortage: Insulin Lispro-aabc Injection (Eli Lilly and Co.)

    Insulin Lispro-aabc Injection — reported in shortage by Eli Lilly and Co.. Therapeutic category: Endocrinology/Metabolism.